Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Hospira 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Hospira 3Q

Specialty Injectable Pharmaceuticals sales, including U.S. sales of Precedex, meropenem, vancomycin and heparin, help offset the temporary discontinuation of U.S. sales of oxaliplatin (due to a litigation settlement) and the decline in Medication Manageme

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Hospira 3Q

3Q Revenues: $949.3 million (-6%)

3Q Earnings: $71.4 million (-39%)

YTD Revenues: $2.9 billion (+4%)

YTD Earnings: $296.6 million (-4%)

Comments: Specialty Injectable Pharmaceuticals sales, including U.S. sales of Precedex, meropenem, vancomycin and heparin, help offset the temporary discontinuation of U.S. sales of oxaliplatin (due to a litigation settlement) and the decline in Medication Management Systems (-6% to $152.1 million). Specialty Injectables sales were $558.7 million in the quarter (-3%). Other Pharma revenues were $137.9 million (-12%). YTD Specialty Injectables sales were up 17% to $1.7 billion. YTD Medication Management Systems revenue was down 8% to $445.3 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics